Antimicrobial screening and molecular docking of synthesized 4,6-di(1H-indol-3-yl)-1,6-dihydropyrimidin-2-amine
M. Abshana Begam , N. Akalya , R. Murugesan , K. Dass , N. Prakash
Intelligent Pharmacy ›› 2024, Vol. 2 ›› Issue (4) : 571 -577.
Antimicrobial screening and molecular docking of synthesized 4,6-di(1H-indol-3-yl)-1,6-dihydropyrimidin-2-amine
A variety of medicinal compounds, including 4,6-di(1H-indol-3-yl)-1,6-dihydropyrimidin-2-amine, were synthesized through a single-step, multicomponent, stepwise reaction. In this reaction, a mixture of 1H-indole-3-Carbaldehyde, 1-(1H-indol-3-yl) ethanone and guanidine nitrate in ethanol was refluxed. The synthesized compounds were characterized using 1H NMR and 13C NMR studies and their antimicrobial activities against Escherichia coli, Staphylococcus aureus, Aspergillus niger and Aspergillus flavus were evaluated. Molecular docking analysis revealed specific amino acid residues (LEU704, GLY708, LEU707, GLN711, MET749, PHE764, VAL746, MET787, MET745, LEU873, HIS874, VA; 903, MET742, ILE898, MET895, ILE899, TRP741, THR877, P HE 876, LEU701, MET780) are involved in the interaction between androgen receptor and ligand. The optimal interaction and docking score were observed (7.0 kcal/mol).
Aldehyde / Antimicrobial activity / Chalcone / Docking / 1H-indole-3-carbaldehyde
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
OECD. Guidance Document on Developing and Assessing Adverse Outcome Pathways. Vol. 184. Paris, France: OECD; 2013. |
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
Samy Christy Rani Arokia, Karunanithi Kalaimathi, Sheshadhri Jayasree, Rengarajan Murugesan, Srinivasan Prabhu. Pinkie cherian. (R)- (+)- rosmarinic acid as an inhibitor of herpes and dengue virus replication: an in silico assessment. Rev Bra deFar. 2023;33:543–550. |
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
/
| 〈 |
|
〉 |